Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Treasury Shares (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Treasury Shares for 13 consecutive years, with $30211.0 as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares fell 98.69% year-over-year to $30211.0; the TTM value through Mar 2026 reached $30211.0, down 98.69%, while the annual FY2025 figure was $2.1 million, 16.7% down from the prior year.
  • Treasury Shares hit $6.8 million in Q4 2023 for Viking Therapeutics, roughly flat from $6.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.9 million in Q3 2023 and bottomed at $30211.0 in Q1 2026.
  • Average Treasury Shares over 5 years is $1.5 million, with a median of $1.9 million recorded in 2022.
  • On a YoY basis, Treasury Shares climbed as much as 32.69% in 2023 and fell as far as 0.0% in 2023.
  • Viking Therapeutics' Treasury Shares stood at $6.8 million in 2022, then changed by 0.0% to $6.8 million in 2023.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $30211.0, $2.1 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.